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ABSTRACT
Cancer cachexia is a syndrome characterized by loss of skeletal muscle mass, 
inflammation, anorexia and anemia, contributing to patient fatigue and reduced 
quality of life. In addition to nutritional approaches, exercise training (EX) has been 
proposed as a suitable tool to manage cachexia. In the present work the effect of 
mild exercise training, coupled to erythropoietin (EPO) administration to prevent 
anemia, has been tested in tumor-bearing mice. In the C26 hosts, acute exercise 
does not prevent and even worsens muscle wasting. Such pattern is prevented by 
EPO co-administration or by the adoption of a chronic exercise protocol. EX and EPO 
co-treatment spares oxidative myofibers from atrophy and counteracts the oxidative 
to glycolytic shift, inducing PGC-1α. LLC hosts are responsive to exercise and their 
treatment with the EX-EPO combination prevents the loss of muscle strength and the 
onset of mitochondrial ultrastructural alterations, while increases muscle oxidative 
capacity and intracellular ATP content, likely depending on PGC-1α induction and 
mitophagy promotion. Consistently, muscle-specific PGC-1α overexpression prevents 
LLC-induced muscle atrophy and Atrogin-1 hyperexpression. Overall, the present 
data suggest that low intensisty exercise can be an effective tool to be included in 
combined therapeutic approaches against cancer cachexia, provided that anemia is 
coincidently treated in order to enhance the beneficial action of exercise.
INTRODUCTION
Cancer cachexia is a multifactorial syndrome 
frequently occurring in association with different types 
of cancers. It is characterized by a complex interplay 
of factors, resulting in poor quality of life, decreased 
tolerance to anticancer therapies and reduced survival 
[1]. The pathophysiology of cachexia includes increased 
protein catabolism, systemic inflammation, hormonal 
disturbances and down-regulation of anabolic signals. 
Depletion of the skeletal muscle mass, not necessarily 
associated with the loss of fat mass, is the most relevant 
feature of cachexia. Such a pattern results in progressive 
reduction of muscle strength, endurance and exercise 
capacity [2], and cannot be fully reversed by conventional 
nutritional support. 
A frequent comorbidity of cancer is anemia 
(hemoglobin level < 12 g/dl), that occurs in approximately 
40% of cancer patients. Its incidence depends on a number 
of variables such as tumor site and origin, progression, 
stage, extent of disease and cancer treatment [3]. Anemia 
potentially promotes the progression of wasting in 
cachectic patients [4]. In this regard, a direct correlation 
between hemoglobin levels and the quality of life of 
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cancer patients has been established, the onset of anemia 
being related to decreased functional status and survival 
[3]. Anemia and muscle wasting are mainly responsible for 
fatigue, hampering patient daily activities and independent 
life. In peripheral tissues, skeletal muscle included, 
anemia can cause hypoxia, with consequent intracellular 
acidification and reduction of oxidative metabolism. These 
changes might result, respectively, in increased protein 
degradation and cell damage, eventually leading to muscle 
wasting [5].
The most effective pharmacological treatment 
for anemia is erythropoietin (EPO), an endogenous 
cytokine/hormone able to stimulate erythropoiesis. EPO 
acts binding to its specific receptor (EPO-R), belonging 
to the family of cytokine receptors characterized by a 
single transmembrane domain [6]. EPO has pleiotropic 
functions, since EPO-R expression is not restricted to 
hematopoietic cells, but is present in heart [7], skeletal 
muscle [6] and adipose tissue [8]. In this regard, in the 
skeletal muscle of EPO-deficient mice the expression of 
genes related to mitochondrial function is low, while genes 
involved in proteolysis and hypoxia are overexpressed, 
suggesting that EPO plays a relevant role in muscle tissue 
[9]. Consistently, EPO administration to rats rapidly 
stimulates glucose metabolism and muscle anabolism 
[10]. Recently, EPO and EPO-R have been involved in 
muscle regeneration. Indeed, mice with high circulating 
EPO show an improved recovery from muscle injury and, 
conversely, muscles lacking EPO-R display an increased 
susceptibility to cardiotoxin-induced damage [11]. Finally, 
several studies demonstrate that EPO promotes a shift 
from glycolytic to oxidative metabolism [6]. A protective 
action of EPO against muscle wasting could be inferred 
from these observations, glycolytic myofibers being those 
preferentially affected in cancer cachexia [12].
The mechanisms underlying cachexia are still poorly 
understood, and the availability of effective interventions 
is quite limited. In this regard, exercise training has 
been proposed as a mean to improve the quality of life 
of cachectic patients [13]. Indeed, the beneficial effect of 
exercise in counteracting fatigue and exhaustion has been 
extensively demonstrated [14]. According to the adopted 
protocol, exercise training can either increased muscle 
mass or improve cardiovascular function, stimulating 
specific pathways; as a consequence, muscle atrophy or 
fatigue in cancer patients could be improved [13, 15]. 
Since tumor growth induces several metabolic changes 
in the skeletal muscle such as reduced ATP synthesis, 
mitochondrial alterations and shift from oxidative to 
glycolytic metabolism [4], endurance exercise might well 
be proposed to reverse or attenuate all these alterations, 
resulting in prevention/delay of cancer-induced muscle 
wasting. 
Aim of the present study was to verify whether the 
adoption of a low intensity endurance exercise protocol 
could counteract the loss of muscle mass and function 
occurring in experimental cancer cachexia. Exercise has 
been associated with EPO administration in order to test 
if, beyond affecting anemia, EPO could further improve 
exercise effects on muscle wasting.
RESULTS
We previously showed that moderate aerobic 
exercise associated with eicosapentaenoic acid 
administration partially prevented the loss of muscle mass 
and strength in mice bearing the Lewis Lung Carcinoma 
(LLC; [16]), while the same exercise protocol worsened 
muscle wasting in mice hosting the C26 carcinoma [17]. 
Anemia occurs in both LLC or C26 hosts [8] and could 
negatively modulate the response to exercise. To clarify 
this point, in the present study two different exercise 
protocols have been associated with EPO administration 
to tumor-bearing mice. 
Confirming previous observations [18], the growth 
of the C26 tumor results in reduced body weight, food 
intake, muscle strength and mass (Figure 1A, 1B, S1, 
S2). Such a wasting pattern cannot be rescued, or can be 
even worsened, by two weeks of low intensity endurance 
exercise, while the association with EPO improves body 
and heart weight in comparison to trained C26 hosts 
(Figure 1A, S1A). In a second experiment the animals 
have been exercised for eight weeks (6 before and 2 after 
tumor injection). Such a schedule likely results in mice 
adaptation to exercise, allowing to test the susceptibility 
to cachexia in mildly trained animals. At sacrifice, 14 
days after tumor implantation, no differences in body and 
muscle weight can be observed in tumor-bearing mice, 
irrespective of the treatment (exercise with or without 
EPO; Figure 1B, Figure S2A), while the association of 
exercise with EPO partially prevents C26-induced heart 
depletion (Figure 1B). While the two week exercise 
protocol does not affect, or even reduces, food intake 
in the C26 hosts (Figure S1B), eight week training 
prevents C26-induced anorexia (Figure S2B). As for 
muscle function, the reduced muscle strength found in 
tumor-bearing animals is not modified by the two week 
exercise protocol, independently of EPO treatment (Figure 
S1C). By contrast, the eight week training improves grip 
strength, only when combined with EPO (Figure S2C). In 
both experiments EPO administration restores hematocrit 
to normal values (Figure S3B, S4B). 
C26-bearing animals present with spleen hyperplasia 
(Figure S3A, S4A) and high circulating IL-6 levels (Figure 
S3C, S4C). While spleen mass is reduced by both exercise 
protocols (two or eight weeks; Figure S3A, S4A), only 
acute (2 weeks) exercise decreases IL-6 concentrations, 
an effect that is enhanced by co-treatment with EPO 
(Figure S3C, S4C). As for the other tissues examined, the 
two week exercise protocol does not affect liver mass, 
even when associated with EPO administration, while the 
combination EPO-exercise partially prevents the loss of 
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adipose tissue (Figure S3A), confirming previous results 
[8]. The eight week training produces a comparable, 
though not totally overlapping, pattern (Figure S4A).
In order to check if two weeks of low intensity 
endurance exercise and EPO treatment could affect 
muscle fiber type composition and size, myofiber CSA 
has been assessed on SDH stained section (Figure 2A), 
virtually separating the tibialis muscle into two zones, 
according to the prevalence of oxidative or glycolytic 
fibers. C26 growth leads to a significant CSA reduction 
in both oxidative and glycolytic fibers (Figure 2B, S5), 
while the combination of exercise and EPO restores CSA 
in the former, though not in the latter. The presence of 
the tumor also drives an oxidative to glycolytic fiber 
shift, that is reversed by the combined treatment (Figure 
2C). Finally, the expression levels of PGC-1α, a factor 
involved in mitochondrial biogenesis and function, have 
been evaluated in the skeletal muscle of treated and 
untreated tumor-bearing mice. The results show that PGC-
1α expression does not change between controls and C26 
hosts, despite previous observations showing a reduction 
in the latter [18]. Consistently with the increased number 
of oxidative myofibers, the combined treatment EX-EPO 
significantly enhances PGC-1α expression in the skeletal 
muscle of the C26-bearing mice (Figure 2D). 
Since exercise and EPO partially improve cachexia 
in the C26 hosts, such combined approach has been tested 
also in the LLC-bearing mice, where anemia is markedly 
severe. Moreover, four weeks of LLC growth are required 
to lose animal muscle mass and strength (Figure 3A, 3B), 
allowing to adopt an exercise protocol more extended 
than the one used during C26 growth. The results show 
that the low intensity endurance exercise adopted does 
not improve muscle mass in LLC-bearing mice (Figure 
3A), while it is able to rescue muscle strength (Figure 
3B). Cardiac hypertrophy and anemia occur in the LLC 
hosts (Figure 3A, 3C). The former tends to decrease after 
exercise or EPO alone and is completely reversed by the 
combined treatment (Figure 3A), while EPO partially 
corrects the latter (Figure 3C).
Figure 1: Exercise training and EPO do not prevent C26-induced muscle loss. A. Gastrocnemius (GSN), tibialis and heart 
weight in control (C), and C26-bearing mice (C26). C26 groups were subdivided in sedentary, exercised (EX), and exercised EPO-treated 
(EX EPO). B. GSN, tibialis and heart weight in control (C), and C26-bearing mice (C26). C26 groups were subdivided in untreated, 
exercised (EX), EPO-treated (EPO) and exercised EPO-treated (EX EPO) for eight weeks (of exercise). Data (mean±SD) are expressed as 
percentages of C. Significance of the differences: *p < 0,05 vs C, **p < 0,01 vs C, ***p < 0,001 vs C, $p < 0,05 vs C26.
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Figure 2: Exercise training and EPO counteract oxidative fiber atrophy and glycolytic shift stimulating PGC-1α 
expression. A. SDH (succinate dehydrogenase) staining in cross sections of tibialis muscle from control (C), C26-bearing (C26) and 
C26 exercised EPO-treated (EX EPO) mice (2 weeks of exercise). The two micrographs for each group represent two regions with distinct 
frequency of oxidative (Ox) and glycolytic (Glyc) fibers. B. Morphometric analysis of myofiber CSA (cross-sectional area) performed on 
SDH stained sections. Data (mean±SD) are expressed as percentages of controls. C. Quantification of fiber type frequency in the tibialis 
muscle. Data (mean±SD) are expressed as relative percentages. D. PGC-1α nuclear protein expression in the tibialis muscles. Densitometric 
quantifications were normalized according to GAPDH levels. Data (mean±SD) are expressed as percentages of controls. Significance of the 
differences: *p < 0,05 vs C, **p < 0,01 vs C, ***p < 0,001 vs C, $p < 0,05 vs C26, $$p < 0,01 vs C26.
Figure 3: Exercise training and EPO partially prevent cachexia in LLC-bearing mice. Gastrocnemius (GSN), tibialis and 
heart weight A., voluntary grasping strength B. and hematocrit C., in control (C) and LLC-bearing mice (LLC). LLC groups were subdivided 
in sedentary, EPO-treated (EPO), exercised (EX) and exercised EPO-treated (EX EPO)for four weeks. Data (mean±SD) expressed as 
percentages of controls except for hematocrit (absolute values). Significance of the differences: *p < 0,05 vs C, **p < 0,01 vs C, ***p < 
0,001 vs C, $p < 0,05 vs LLC, $$p < 0,01 vs LLC.
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Muscle mitochondria ultra-structure has been 
analyzed in the LLC hosts, in order to investigate 
the effects of exercise and EPO on myofiber energy 
metabolism. In both EDL (glycolytic) and soleus 
(oxidative) muscles LLC growth results in the appearance 
of swollen mitochondria (Figure 4A), similarly to previous 
observations reported in both C26-bearing mice [19] and 
AH-130-bearing rats [20]. Other alterations, previously 
reported in the AH-130 model [20], such as disrupted 
triads and increased mitochondrial area were observed, 
however no quantitative data were obtained. Treatment 
with EPO in association with exercise allows a qualitative 
(Figure 4A) and, despite the limitations imposed by 
sample size and area assayed, quantitative (Figure S6) 
recovery of mitochondrial structure in the skeletal muscle 
of LLC-bearing mice. In accordance with the above 
reported mitochondrial damage, myofiber oxidative 
capacity (SDH activity) is reduced in untreated LLC hosts 
while is restored to physiological values by both EPO 
and exercise, alone or combined (Figure 4B). Of interest, 
exercise, associated or not with EPO, increases SDH 
activity also in comparison with control mice, suggesting 
that the tumor-bearing condition is permissive for muscle 
mitochondrial biogenesis. Dysfunctional mitochondria 
could lead to impaired intracellular energy stores (ATP), 
also due to mitochondrial energy uncoupling and increased 
glycolysis [4]. Consistently, muscle ATP intracellular 
content in tumor-bearing mice is decreased (Figure 4C). 
The administration of EPO alone restores the ATP content 
to control values, while no significant differences can 
be observed in exercised LLC host, in the absence or 
in the presence of EPO. This latter observation is quite 
unexpected, in view of the above reported results showing 
that EPO associated with exercise promotes mitochondrial 
structure recovery (see above).
From a mechanistic point of view, the recovery of 
mitochondrial structure and function can be explained 
again by PGC-1α induction, since both protein (Figure 
Figure 4: Exercise training and EPO restore mitochondrial morphology in LLC-bearing mice. A. Transmission electron 
microscope images of EDL and soleus longitudinal sections, in control (C), LLC-bearing mice (LLC) and exercised EPO-treated (EX 
EPO). Black arrows indicate altered mitochondria. Scale bar = 500 nm. Quantification of SDH (succinate dehydrogenase) activity in tibilais 
B. and ATP intracellular content in gastrocnemius (GSN) muscle (C., expressed as % of control) of control (C) and LLC-bearing mice 
(LLC). LLC groups were subdivided in sedentary, EPO-treated (EPO), exercised (EX), and exercised EPO-treated (EX EPO). Significance 
of the differences: *p < 0,05 vs C, **p < 0,01 vs C, ***p < 0,001 vs C $$p < 0,01 vs LLC, $$$p < 0,001 vs LLC.
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5A) and mRNA (Figure 5B) levels increase in the muscle 
of LLC-bearing mice after EX and EPO. Dysfunctional 
mitochondria are normally degraded by mitophagy [21]. 
The results shown in the present study demonstrate that 
in the muscle of the LLC hosts a shift from microtubule-
associated (I) to autophagosome-associated LC3B (II) 
occurs. This is paralleled by increased expression of the 
mitophagy regulator Bnip3, suggesting the accumulation 
of damaged mitochondria. In the EX EPO group, both 
LC3B isoforms are makedly reduced and Bnip3 level 
is normalized, in line with an efficient mitochondrial 
clearance (Figure 5A).
The gene expression analysis (Figure 5B) shows that 
EPO action increases EPO-R, while exercise stimulates 
myoglobin (MB), probably due to the increased oxygen 
demand. As a hallmark of protein catabolism, atrogin-1 
expression increases in the LLC-bearing mice, and 
consistently with the unaffected muscle mass, no treatment 
proves able to prevent such increase. Consistently with 
PGC-1α levels, exercise, combined or not with EPO, 
promotes the expression of the mitochondrial biogenesis 
related gene NRF1, while no changes occur in the levels 
of PGC-1β mRNA. The promotion of mitochondrial 
biogenesis by EX and EPO is paralleled by the increase 
of Nix and Bnip3 mRNA. As for Bnip3, such qualitative 
difference with protein levels suggests that this regulator 
of mitophagy can be modulated at the post-translational 
level. Finally, the transcript levels of two important 
regulators of mitochondrial fission, namely DRP-1 and 
Fis-1, that per se could induce muscle atrophy [22], are 
unchanged in all the experimental conditions.
The effects of endurance exercise can be mimicked 
by overexpression of PGC-1α, that was shown to prevent 
atrophy induced by denervation, diabetes, uremia and 
Figure 5: Exercise training and EPO regulate bioenergetics-related gene and protein expression in LLC-bearing mice. 
A. Protein expression analysis of PGC-1α, LC3B (either in native or lipidated form, -I and -II, respectively) and Bnip3 corrected for tubulin 
abundance in gastrocnemius (GSN) muscle of control (C) and LLC-bearing mice (LLC). LLC groups were subdivided in sedentary, EPO-
treated (EPO), exercised (EX), and exercised EPO-treated (EX EPO). Data (mean±SD) expressed as % of controls. B Gene expression 
analysis of EPOR, myoglobin (MB), Atrogin-1, PGC-1alpha, PGC-1beta, NRF1, Nix, Bnip3, DRP-1 and Fis-1 in the tibialis anterior 
muscle. Specific mRNA abundance was corrected for the mean of TBP (TATA box-binding protein) and β-actin levels on individual 
samples. Data (mean±SE) are compared by 2-way ANOVA. Significance of the differences: *p < 0,05 vs C, **p < 0,01 vs C, ***p < 0,001 
vs C, $p < 0,05 vs LLC, $$p < 0,01 vs LLC, $$$p < 0,001 vs LLC.
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unloading [23-25]. No information are available about 
the effectiveness of PGC-1α hyperexpression on cancer-
induced muscle wasting. For this reason, male and female 
transgenic mice overexpressing PGC-1α specifically in 
the skeletal muscle have been injected with LLC cells. 
As for male LLC hosts, the resulting tumors are markedly 
larger than in wild-type littermates (6.08 ± 2.42 g vs 3.34 ± 
1.52 g, respectively; n = 8, p = 0.015). By contrast, tumor 
mass is comparable in wild type or transgenic female mice 
(3.20 ± 2.30 g vs 3.01 ± 2.23 g, respectively; n = 8, p = 
0.874), which is not consistent with previous data [26]. 
Nonetheless, irrespective of the increased tumor size, the 
loss of muscle mass is comparable in transgenic and in 
wild-type male mice (Figure S7A). Not only, myofiber 
CSA is even larger in transgenic LLC-bearing male mice 
than in wild-type tumor hosts (Figure S7B). The other way 
round, PGC-1α overexpression in the skeletal muscle of 
LLC-bearing female mice restores both tibialis muscle 
weight and myofiber CSA to the control value (Figure 
6A, 6B). A similar, although not complete, rescue can 
be observed for the GSN mass (Figure 6A), despite this 
muscle weights markedly less in control PGC-1α than in 
WT mice, likely due to the distinct fiber composition in 
transgenic mice presenting almost the totality of oxidative 
fibers, known to be smaller than the glycolytic ones. 
As for tumor-induced heart hypertrophy, this was not 
affected or was even increased by the transgene, PGC-
1α mice presenting with a mild heart hypertrophy even 
in the absence of the tumor (Figure 6A). Consistently 
with the protection against muscle wasting, in the PGC-
1α transgenic females the increase of muscle atrogin-1 
levels is less marked than in WT animals (Figure 6C). Of 
interest, the expression of both muscle-specific ubiquitin 
ligases atrogin-1 and MuRF1 is reduced in healthy PGC-
1α transgenic mice with respect to wild-type controls 
(Figure 6C).
DISCUSSION
Effective treatments for the prevention of cachexia 
Figure 6: PGC-1α overexpression prevents cachexia in LLC-bearing mice. Gastrocnemius (GSN), tibialis (TIB) and heart 
weight A. and tibialis fiber CSA B. in female control WT (C WT), PGC (C PGC) and LLC-bearing mice WT (LLC WT) and PGC (LLC 
PGC). Data (mean±SD) are expressed as percentages of C WT. C. Gene expression analysis of Atrogin-1 and MuRF1 transcripts. Specific 
mRNA abundance was corrected for the mean of TBP (TATA box-binding protein) and β-actin levels on individual samples. Data (means 
± SE) are compared by 2-way ANOVA. Significance of the differences: *p< 0,05 vs C WT, **p < 0,01 vs C WT, ***p < 0,001 vs C WT, $p 
< 0,05 vs LLC WT, #p < 0,05 vs C PGC, ##p < 0,01 vs C PGC.
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are lacking. In this regard, several clinical trials are 
ongoing, however most of them are based on the use of 
nutritional and pharmacological (mainly orexigenic) 
interventions aimed at preventing body weight loss 
and muscle wasting. By contrast, the effect of exercise 
training has been explored only marginally [15], even 
in experimental models of cachexia [17], despite in 
physiological conditions exercise is the most effective 
strategy to improve muscle mass and function. 
Muscle strength and endurance are markedly 
impaired in cachexia and many cancer patients experience 
chronic fatigue, as a consequence of the tumor and/or 
of the superimposed anti-neoplastic therapies. Chronic 
fatigue and comorbidities, such as anemia and cardiac 
dysfunctions, are limiting factors for practicing physical 
activity [17]. Consistently, the data reported in the present 
study show that exercise does not improve skeletal 
muscle wasting in the C26-bearing mice, in which 
cachexia is associated with anemia (present work) and 
cardiac alterations [27]. In this regard, cardiovascular 
perturbations have been reported also in colorectal 
cancer patients, independently from chemotherapy 
[28], while anemia has been proposed to depend on a 
direct action of the tumor, on anti-cancer treatment, or 
both [3]. Considering that anemia occurs in about 40% 
of cancer patients or even more after chemotherapy [3] 
and that potentially limits the beneficial effects exerted 
by exercise, its correction should be achieved before 
suggesting exercise as a mean to prevent/correct cachexia. 
Indeed, our observations show that EPO administration to 
exercised C26 hosts partially prevents both CSA reduction 
in oxidative myofibers and the shift from oxidative to 
glycolytic fiber type. 
EPO is not free from side effects, mainly 
cardiovascular events reported in patients affected by 
heart or chronic kidney diseases, undergoing prolonged 
EPO administration [29, 30]. For these reasons, safety 
evaluation in cachectic cancer patients would be required. 
However the schedule proposed for EPO administration in 
the present study is ‘acute’ and would be carried out only 
in anemic cancer patients to allow exercise practicing.
The mechanisms accounting for EPO effectiveness 
could go beyond the stimulation of erythropoiesis. 
Indeed, plenty of data are available about the cardio-
protective action of EPO [30], and recent results suggest 
that different regions of the EPO molecule account for the 
erythropoietic and the immunomodulatory action [31]. 
The results shown in the present study demonstrate that 
both EPO and exercise are required to restore the normal 
heart weight in LLC-bearing mice, where anemia is more 
severe than in the C26 hosts, suggesting an additive and 
coordinated action of the two treatments. However, LLC-
bearing mice are hyporesponsive to EPO since the severe 
anemia could only partially be corrected, possibly due 
Figure 7: Proposed mechanism of action of exercise, EPO and PGC-1α in counteracting tumor-induced muscle 
alterations. See text for further details.
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to inflammation that antagonizes erythropoiesis and/or 
excessive erythrocyte cytolysis[32].Being the pathogenesis 
of cachexia a multifactorial process, it is likely that EPO 
and exercise act on different targets, improving anemia 
and muscle strength, respectively. In addition, both could 
positively impinge on heart function.
The inflammatory response is another crucial event 
in the pathogenesis of cancer cachexia. In this regard, 
the data shown in the present study confirm previous 
observations indicating that the levels of circulating IL-
6, a pro-inflammatory cytokine that plays a pivotal role 
in the onset and progression of cachexia [33], markedly 
increase in tumor-bearing mice. Further supporting 
the idea that a combined treatment is the best choice to 
address cancer cachexia, the association between exercise 
and EPO reduces circulating IL-6, even though such effect 
is lost when exercise starts long before tumor injection, 
likely due to an adaptation to the exercise protocol in the 
absence of a reinforcement in running speed and time. The 
anti-inflammatory action of exercise is well-established 
and has been demonstrated in both healthy subjects [34] 
and cancer patients at early stages of the disease [35]. 
In cachectic cancer patients, an exercise-mediated anti-
inflammatory action would be clinically relevant, since 
the occurrence of inflammation negatively impinges on 
diagnosis, staging of cachexia [1, 36], and patient survival 
[37].
The occurrence of muscle mitochondrial dysfunction 
in cachexia has been demonstrated by a number of studies 
[20, 38, 39]. The data here reported confirm that both 
mitochondrial structure and function are altered in the 
skeletal muscle of tumor-bearing mice, and that such 
changes can be rescued by the combined treatment with 
EPO and exercise. In this regard, several studies suggest 
that EPO plays a role in the regulation of mitochondrial 
function: it has been shown to stimulate muscle fat 
oxidation and to prevent diet-induced obesity in mice 
[40], to promote muscle mitochondrial biogenesis in rats 
[41] and to enhance mitochondrial function (oxidative 
phosphorylation and electron transport capacity) in 
humans [42]. These observations are consistent with the 
glycolytic to oxidative myofiber shift observed in the C26-
bearing mice as well as with the increased SDH activity 
occurring in the LLC hosts, both suggesting that the 
combination of EPO and exercise stimulates mitochondrial 
biogenesis. Of interest, EPO alone is unable to prevent 
the accumulation of dysfunctional mitochondria in LLC-
bearing mice, suggesting that between EPO and exercise, 
the latter is leader in driving the action on mitochondria, 
consistently with a previous report showing reduced 
mitochondrial damage in exercised doxorubicin-treated 
rats [43].
In addition to reduced muscle mass, also contractile 
dysfunction has been proposed to drive both muscle 
weakness and fatigue occurring in the C26-bearing mice 
[44]. In this regard, protein hypercatabolism mainly 
accounts for muscle depletion, while impaired muscle 
‘quality’ leads to contractile dysfunction; this latter, in 
particular, mainly depends on the lack of energy, i.e. ATP 
intracellular content. So far, most of the interventions 
proposed to prevent cachexia are aimed to preserve 
muscle mass, while the rescue of muscle quality, even 
if seldom pursued, would prevent the loss of ATP 
production, restoring muscle energetics. No alterations 
in the efficiency of ATP synthesis have been found in the 
skeletal muscle of cachectic rats with peritoneal carcinosis 
[38], while in vivo ATP synthesis rate is markedly reduced 
in LLC-bearing mice [45]. Our results confirm the strong 
reduction of ATP intracellular storage, that is reversed by 
EPO administration, though not by exercise, supporting a 
direct role of EPO in the regulation of muscle energetics. 
Such a role is further supported by the observation that 
EPO alone is sufficient to increase PGC-1α expression, 
confirming similar results reported in healthy rats [41].
Regarding mitochondrial dynamics, our gene study 
shows that, while mitochondrial fission-related transcripts 
are not affected by exercise, combined or not with EPO, 
those related to mitophagy are increased, likely allowing 
the removal of damaged mitochondria. Such hypothesis 
is strengthened by the recent demonstration that PGC-
1α plays a regulatory role on mitophagy in the skeletal 
muscle [21]. Moreover, our observations suggest that 
the exercise protocol adopted is well tolerated in LLC-
bearing mice. Indeed when endurance exercise is 
excessive, mitochondrial fission increases in the absence 
of mitophagy induction [46]. Our results are partially 
confirmed by a study performed in APC Min/+ cachectic 
mice, where the reduction of mitochondrial content is 
associated with PGC-1α and mitochondrial fusion protein 
repression, that is effectively prevented by either IL-6 
blockade or exercise [39]. Most of the studies describing 
muscle mitochondrial alterations confer to PGC-1α 
reduced expression a causative role. Consistently, PGC-
1α overexpression has been shown to effectively prevent 
muscle atrophy in certain conditions [23], acting as an 
exercise mimetic. In agreement with these observations, 
the present study shows that PGC-1α overexpression 
proves effective in preventing LLC-induced muscle 
wasting. Such a result does not comply with a previous 
report suggesting that skeletal muscle hypertrophy and 
resistance to LLC-induced muscle wasting is exclusively 
regulated by PGC-1α4, a non-canonical resistance 
training-induced splice variant of the PGC-1α gene [47]. 
However, recent data obtained in humans question the 
specificity of PGC-1α4 in mediating exercise-induced 
hypertrophy, since all PGC-1α isoforms are induced after 
exercise regardless of the mode [48]. Nonetheless, the 
mode of exercise could be relevant to the effectiveness of 
such an approach in cancer patients, resistance favoring 
the maintenance of muscle mass and endurance improving 
muscle quality. It is likely that the integration of both 
components will provide the most beneficial effect.
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In conclusion, our results highlight the importance 
of a combined approach in order to target at least some 
of the alterations occurring in cachectic patients (Figure 
7). On a first line, EPO administration would prevent 
cancer-induced anemia and boost exercise effectiveness, 
counteracting fatigue. As for the skeletal muscle, the 
association of EPO administration to moderate exercise 
could promote, through stimulation of PGC-1α expression, 
both mitochondrial biogenesis and turnover, improving 
muscle quality and function. Such approach looks 
feasible and provides the scientific bases and mechanistic 
support for translating the preclinical data into clinical 
trials exploring, in a combined therapeutic strategy, the 
effectiveness of exercise for countering cachexia.
MATERIALS AND METHODS
Animals and experimental design
Male 6 week old Balb/C or C57BL/6 (Interfauna, 
Spain) and both male and female C57BL/6-Tg(Ckm-
Ppargc1a)31Brsp/j (overexpressing PGC-1α1 in the 
skeletal muscle [49]; the Jackson Laboratory, USA) 
mice were maintained on a regular dark-light cycle 
(light from 08:00 to 20:00), with free access to food and 
water during the whole experimental period. Animals 
were cared for in compliance with the Policy on Human 
Care and Use of Laboratory Animals (ILAR 2011). The 
Bioethical Committees of the University of Barcelona and 
Torino approved the experimental protocols. All animal 
manipulations were made in accordance with the European 
Community guidelines for the use of laboratory animals.
Mice were randomized and divided into two groups, 
namely controls (C) and tumor bearers (TB). TB mice were 
inoculated subcutaneously in the back with 5x105 Colon26 
(C26) or Lewis Lung carcinoma (LLC) cells. C26 and 
LLC cells were maintained in vitro in DMEM (Invitrogen) 
supplemented with 10% FBS, 100 U/ml penicillin, 100 
µg/ml streptomycin, 100 µg/ml sodium pyruvate, 2 mM 
L-glutamine, at 37°C in a humidified atmosphere of 5% 
CO2 in air. The day of tumor implantation, cells were 
trypsinized, resuspended in sterile saline, and implanted 
in the back of the animals. Tumor-bearing mice were 
divided into different groups: sedentary (C26 and LLC), 
submitted to endurance exercise (C26 EX and LLC 
EX), treated every three days with an intraperitoneal 
injection of recombinant human EPO (100 IU, see [50]; 
C26 EPO and LLC EPO) and submitted to endurance 
exercise and erythropoietin treatment (C26 EX EPO and 
LLC EX EPO). Transgenic mice were randomized and 
divided into two groups, namely controls (C PGC) and 
tumor bearers (LLC PGC). As for the exercise protocol, 
mice were exercised on a Panlab/Harvard-Apparatus 
treadmill (Barcelona, Spain). Mice were exercised 5 days/
week starting the day after tumor injection for both C26 
and LLC. In a subsequent experiment on C26 mice, the 
animals were exercised starting 6 weeks before tumor 
injection until sacrifice. Mice ran for 45 minutes at the 
speed of 14 m/minute (see [16] for details). 
Animal weight and food intake were recorded daily, 
starting from the day of tumor implantation. Control and 
tumor-bearing mice were sacrificed under anesthesia 14 
or 28 days after C26 or LLC implantation, respectively. 
Several muscles and tissues were rapidly excised, 
weighed, frozen in melting isopentane and stored at -80°C 
for further analysis. 
Grip force assessment
Muscle strength was assessed by the grip-strength 
test as previously described [16] using a Panlab-Harvard 
Apparatus device. Three measurements were taken for 
each mouse on both baseline and sacrifice day.
Hematocrit
Blood was collected from anaesthetized mice 
by cardiac puncture. A drop was used to fill hematocrit 
capillary tubes that were centrifuged in a specific 
centrifuge for 5 min at 800 x g. Hematocrit was expressed 
as volume percentage of erythrocytes in the blood.
Histology, SDH staining and total activity
During sacrifice, both tibialis muscles from each 
animal were rapidly excised. One was snap frozen in 
liquid nitrogen for enzymatic activity and western blotting, 
the other was mounted in OCT and frozen in melting 
isopentane for histology. Transverse sections (10 μM) 
were cut on a cryostat and stained for SDH (succinate 
dehydrogenase). Briefly, cryosection were incubated for 
30 min at 37°C with 1 mg/ml NTB (nitrotetrazolium blue 
chloride) and 27 mg/ml Na-succinate in PBS, washed three 
times in PBS, mounted with glycerol and photographed. 
Fiber cross-sectional area (CSA) was determined using 
the Image J software on randomly chosen 100 individual 
fibers in the two regions of the muscle composed mainly 
by oxidative or glycolytic fibers, respectively. As for the 
total SDH activity, the muscles were homogenized (5% wt/
vol) in ice-cold 150 mM NaCl, 10 mM KH2PO4, 0.1 mM 
EGTA and centrifuged 5 min at 800 x g. The supernatant 
was collected and total protein content measured using 
the BCA protein assay (Pierce, Thermo Fisher Scientific, 
USA). Protein homogenates (50 μl) were incubated with 
200 µl reaction buffer containing 10 mM Na-succinate, 
50 µg/ml DCPIP, 10 mM phosphate buffer (pH 7.4), 2 
mM KCN, 10 mM CaCl2, 0.05% BSA. The absorbance 
at 600 nm was measured after 0, 3 and 20 min. The rate of 
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absorbance decrease between 3 and 20 min was corrected 
for the protein loading and used to calculate the SDH 
content. 
Electron microscopy
EDL and soleus muscle specimens of 1 mm3 were 
prepared under a stereomicroscope and fixed for 24 h at 
4°C with 2% parafomaldehyde and 2.5% glutaraldehyde 
in phosphate buffer. After washing, samples were 
postfixed with 1% osmium tetroxide and 0.8% potassium 
ferricyanide at 4°C and finally dehydrated in acetone, 
infiltrated with Epon resin during 48 h, embedded in 
the same resin positioned to obtain longitudinal sections 
and polymerised at 60°C during 48 h. After semi-thin 
sectioning and field selection, ultrathin sections were 
obtained using a Leica Ultracut UC6 ultramicrotome and 
mounted on Formvar-coated copper grids. Sections were 
stained with 2% uranyl acetate in water and lead citrate 
and observed in a JEM-1010 electron microscope (Jeol, 
Japan) equipped with a CCD camera SIS Megaview III and 
the AnalySIS software. Intermyofibrillar mitochondrial 
morphology was classified into unchanged and altered 
(swelling-related ultrastructural changes). Mitochondrial 
counting was performed computing the average number of 
altered mitochondria in 3 randomly taken micrographs per 
sample and 3 samples per experimental group.
Intracellular ATP content
ATP was determined by bioluminescence using 
a commercially available kit (ATP Bioluminescence 
Assay Kit CLS II; Roche) according to manufacturer’s 
recommendations. Briefly, gastrocnemius muscles were 
homogenized in PBS (10% wt/vol). Muscle homogenates 
were then diluted 10 times in 100 mM Tris, 4 mM 
EDTA (pH 7.75 ), incubated 2 minutes at 100°C, and 
centrifuged 1 minute at 1000 x g and the supernatant 
collected. An aliquot of sample (50 μl) was added to 50 
µL of the luciferase reagent in a multiwell black plate (96 
wells - Packard). The luminescence was measured in a 
Luminometer at 562 nm with an integration time of 10 
seconds. ATP concentrations were obtained from a log-log 
plot of the standard curve data.
Western blotting
Tibialis muscles were homogenized in 10 mM 
HEPES, pH 7.5, containing 10 mM MgCl2, 5 mM KCl, 
0.1mM EDTA and 0.1% Triton X-100, with freshly added 
protease and phosphatase inhibitor cocktails, centrifuged 
at 3000 x g for 5 min at 4°C, and the supernatant collected 
as cytosolic extract. The pellet was resuspended in 20 mM 
HEPES, pH 7.9, containing 1.5 mM MgCl2, 500 mM 
NaCl, 0.2mM EDTA and 25% glycerol, with freshly added 
protease and phosphatase inhibitor cocktails, incubated 
on ice for 30 min, centrifuged at 3000 x g for 5 min at 
4°C, and the supernatant collected as nuclear extract. 
Protein concentration was measured using the BCA 
protein assay (Pierce, Thermo Fisher Scientific, USA). 
Equal amounts of nuclear protein (20 µg) were heat-
denaturated in sample-loading buffer (50 mM Tris-HCl, 
pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 
10% glycerol), resolved by SDS-PAGE and transferred 
to nitrocellulose membranes (Bio-Rad, USA). The filters 
were blocked with Tris-buffered saline (TBS) containing 
0.05% Tween and 5% non-fat dry milk and then incubated 
overnight with an antibody directed against PGC-1α 
(Millipore, USA). Peroxidase-conjugated IgG (Bio-Rad, 
USA) were used as secondary antibodies. Membrane-
bound immune complexes were detected by an enhanced 
chemiluminescence system (Santa Cruz Biotechnology, 
USA) on a photon-sensitive film (Hyperfilm ECL, GE 
Healthcare, Italy). Protein loading was normalized 
according to GAPDH (Santa Cruz biotechnology, USA) 
expression. Quantification of the bands was performed by 
densitometric analysis using a specific software (TotalLab, 
NonLinear Dynamics, UK). 
RT-PCR
Total RNA was obtained using the TriPure reagent 
(Roche, USA) following manufacturer’s instructions. 
RNA concentration was determined fluorometrically using 
the Ribogreen reagent (Invitrogen, USA). Total mRNA 
was retro-transcribed using the i-Script cDNA synthesis 
kit (Bio-Rad, USA). Transcript levels were determined by 
real-time PCR using the SsoFast Evagreen Supermix and 
the MiniOpticon thermal cycler (Bio-Rad, USA). Primer 
sequences are given in the supplemental material section.
Data analysis and presentation
All the results are expressed as means ± SD, except 
for gene expression (means ± SEM). The significance 
of the differences was evaluated by analysis of variance 
(ANOVA) followed by Tukey’s test.
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